Summary: Postherpetic neuralgia (PHN), a common complication of herpes zoster, which results from reactivation of varicella zoster virus, is a challenging neuropathic pain syndrome. The incidence and severity of herpes zoster and PHN increases with immune impairment or age and may become a greater burden both in terms of health economics and individual suffering. A clearer understanding of the underlying mechanisms of this disease and translation of preclinical outcomes to the clinic may lead to more efficacious treatment options. Here we give an overview of recent findings from preclinical models and clinical research on PHN.
INTRODUCTION
Postherpetic neuralgia is a challenging chronic neuropathic pain syndrome. It occurs after reactivation of a latent infection by varicella zoster virus (VZV) within sensory neurons 1 causes the distinctive clinical condition known as herpes zoster (HZ) and commonly called shingles. Although most patients recover completely after several months, a number will be left with persistent pain, known as postherpetic neuralgia (PHN). Currently available therapies are of variable benefit, and there is a clear need to improve our clinical approach either by improved treatments or by developing effective prevention strategies. 1, 2 The nature of the interaction between the virus and host cells is unclear and underinvestigated. The promise of eventual eradication by vaccination programs remains to be properly evaluated.
The etiology of disease progression is poorly understood. After resolution of the primary infection, known as varicella or chickenpox, VZV establishes a latent infection in sensory ganglia that persists for the lifetime of the host. 3 In some circumstances, often associated with increasing age or in situations of immune compromise, HZ may develop. 4, 5 Clinical features of HZ can be variable and include pain and abnormal sensations that may continue after the development of PHN. 6 -11 The incidence of HZ and PHN is difficult to estimate accurately because of inconsistencies in diagnosis and data collection. Studies indicate an incidence of 5.23 cases of HZ per 1000 person-years, with 13.7% of those having evidence of PHN after 3 months, or an incidence of 0.4 per 1000 person-years for PHN (compared with 0.15 for diabetic neuropathy). 12, 13 Estimates for HZ range from 5 to 12 cases per 1000 each year over all age groups. 14 
POSTHERPETIC NEURALGIA
In the majority of patients presenting with HZ, the characteristic rash and associated acute zoster pain disappear within 1-2 months, but for some patients the acute symptoms of HZ may be followed by irreversible skin damage and sensory abnormalities, resulting in a persistent pain that can continue for months or years. Postherpetic neuralgia is the most common complication of HZ. 15 Risk factors include age, severity of acute HZ pain, extent of rash, and presence and duration of prodromal pain. 16 -18 Other complications of HZ can include encephalitis, retinitis, and pruritus. addition, sensory stimuli can evoke pain (e.g., dynamic mechanical allodynia evoked by innocuous stimulation, such as light touching of the skin). 22, 23 In addition, impaired sleep, emotional distress, and depression are common. In combination, these manifestations of PHN can lead to a reduction in the quality of life and activity levels.
At present, zoster-associated pain is used to cover a continuum of pain from the start of prodrome to its resolution, with PHN reserved for cases of significant pain or painful abnormal sensations persisting beyond 3 months after the HZ rash. The time course for the development of persistent pain associated with PHN is between 90 and 120 days after rash appearance. 24 -27 The risk of PHN increases dramatically with age, from 3-4% in adults aged 30 -49 years, to 21% in 60-to 69-yearolds, to 29% in 70-to 79-year-olds, and to 34% in adults over the age of 80 years. 9, 28 As the median age of the developed world population increases, PHN may become a greater burden.
Approximately 70% of PHN patients who also experience ongoing pain and severe dynamic mechanical allodynia show considerable signs of neuronal degeneration and loss of function within the affected tissues. Immunohistochemical investigations and punch biopsies of the affected dermatome show degeneration of small fiber afferents in the skin. 29, 30 Furthermore, functional studies investigating C-fiber axon reflex have demonstrated impaired or abolished chemically evoked antidromic vasodilatation in skin regions with intense dynamic allodynia, indicating a significant loss of cutaneous C-fiber afferents. 31, 32 There is evidence that all sensory fiber types are affected in PHN, with constant pain possibly being associated with damage to nociceptive afferents and paroxysmal pain related to changes in A␤ fibers. 33 Quantitative thermal sensory testing showed greatly increased heat pain thresholds in the affected dermatome of some chronic PHN patients. 34 Thus, there is a subset of PHN patients with pain and loss of cutaneous C-nociceptor function in a region that is coextensive with allodynic skin. Mechanisms underlying allodynia in these patients are still unclear: different subcortical brain areas are activated than with spontaneous pain. 35 There might also be hyperexcitability of nociceptive neurons at the spinal level, due to the loss of inhibitory GABAergic interneurons that occurs after peripheral nerve lesion. 36 After peripheral nerve injury, there are alterations in input to the central nervous system, inducing changes in the sensory processing mechanisms within the spinal dorsal horn. This gives rise to the phenomenon of central sensitization resulting from the increased afferent input generated by injury and noxious stimuli. This increased excitability of nociceptive neurons in the dorsal horn leads to an exaggerated and extended response to subsequent sensory inputs. 37 If central sensitization is established, normally innocuous tactile stimuli become capable of activating spinal cord pain signaling neurons via A␤ low-threshold mechanoreceptors. 38 By this mechanism, light touching of the skin induces mechanical allodynia.
Several clinical observations support the concept of sensitized nociceptors and central sensitization in PHN patients. Approximately 30% of patients with PHN experiencing ongoing pain and severe dynamic mechanical allodynia do not show any loss of sensory function in the affected area, indicating that in these particular groups of patients loss of neurons may be minimal or absent. Accordingly, thermal sensory thresholds in their region of greatest pain are either normal or even decreased, 30, 39 which may reflect peripheral nociceptor sensitization.
PRECLINICAL EVALUATIONS
In vivo models have been developed of the persistent nociception induced by VZV, which results in sensory sensitivity to mechanical and thermal stimuli. 40 -42 The development of behavioral sensitization is dependent on the viral titer injected, with the absence of thermal hyperalgesia observed by Hasnie et al. 43 possibly a result of differences in the viral inoculum concentration. 41 The events through which the presence of the virus in neurons induces sensory sensitivity remain obscure. Techniques to address this are emerging. 44 Viral infection in the sensory dorsal root ganglia (DRG) is confirmed by the presence of the immediate early protein VZV IE62, a protein that is expressed during latency and that is known to be essential for VZV replication and expression in host cells. 41, 45, 46 This protein has been shown to be associated with subpopulations of DRG neurons. 41 Inoculation with different viral strains. in addition to those harvested from patients (with or without PHN), all showed the presence of VZV IE62 in DRG. 43 Both VZV IE62 and IE63 were also present in DRG from an in vitro model of localized infection. 47 Additionally, infection of DRG with VZV resulted in sensitivity to adrenergic stimulation, with a possible mechanism of norepinephrine sensitivity through either or both ␣ 1 -and ␤ 1 -adrenergic receptors. 47 The association of VZV IE62 expression with particular subpopulations of sensory neurons suggest a possible route for influencing cellular mechanisms within these neurons. A key factor in the neural plasticity underlying neuropathic pain is altered gene expression in sensory DRG neurons. 48 -51 Phenotypic alterations in the expression of neurotransmitters, in particular neuropeptides, occurs in both damaged and neighboring afferents after nerve injury. 49, 52 After peripheral nerve injury within large-diameter DRG neurons, there is a marked increase in the expression of neuropeptide Y, 49 but in small-diameter DRG neurons, galanin levels are shown to increase. 49, 52 Similar to the case with nerve injury, after VZV infection there is an upregulation of neuropeptide Y and galanin in DRG neurons. 41 In addition, there also appears to be some axonal damage after VZV infection, as indicated by the induction of activating transcription factor-3 (ATF-3), 41 a protein that is upregulated after nerve axotomy. 53 Whether this is accompanied by any lasting neurodegenerative changes remains to be established.
Increase in the excitability of the nociceptor terminal membrane (and therefore reduction in the amount of further depolarization required to initiate an action potential) occurs when terminals are exposed to sensitizing agents such as inflammatory mediators or neurotrophic factors released during tissue or nerve damage. 50 Voltage-gated sodium channels (Na ϩ channels) are mainly responsible for the rising phase of the action potential, and after nerve injury accumulate in the axon at the injury site and along its length, resulting in foci of hyperexcitability and ectopic action potential discharge in the axon and cell body of injured sensory neurons. 54, 55 Normally, DRG neurons express a number of Na ϩ channel transcripts 56 that can be distinguished by their sensitivity to tetrodotoxin (TTX). 57 Expression of the TTXsensitive Na v 1.3 sodium channel is markedly increased after peripheral nerve damage 48, 58 and after VZV infection. 41 The related TTX-resistant Na v 1.8 is also upregulated after VZV infection, 41 which may represent a promising target, given that knockdown of Na v 1.8 reduces nerve injury-induced behavioral sensitization. 59 Indeed, the sodium channel blocking agents mexiletine and lamotrigine were effective in attenuating VZV-induced behavioral sensitization 41 and are effective analgesics in models of nerve injury and in the clinic. 60 -63 A further phenotypic alteration observed in VZV infected DRG is an upregulation of the ␣ 2 ␦1 subunit of the voltage-gated calcium channel, 41 which is also noted after nerve injury. 64 -66 Such an increase is of particular importance, because the subunit ␣ 2 ␦1 has been proposed as the key target of gabapentin, 67 which (probably by blocking this channel subunit) can suppress ectopic discharges of injured primary afferents and reverse injuryinduced allodynia. 60,62,68 -71 Gabapentin and its analogue pregabalin are effective in the treatment of neuropathic pain, including PHN, [72] [73] [74] and can reduce VZV-induced behavioral reflex sensitization with either acute or chronic administration. 41 Acute administration of the selective -opioid receptor agonist DAMGO did not affect virusinduced behavioral reflex sensitization, 41 whereas chronic administration of morphine did reverse VZV-induced mechanical sensitization. 43 Although clearly a number of receptors and subsequent signaling pathways are involved in the central sensitization that results in sensory hyperexcitability in many chronic pain models, changes in NMDA receptor activation are consistently thought to be a crucial factor underlying central sensitization. 55, 75, 76 Human studies have demonstrated the potential of the NMDA antagonist ketamine in the treatment of various chronic pain conditions, although with significant adverse effects. 77 Local spinal application of an NMDA receptor antagonist attenuated VZV-induced behavioral sensitization. 41 In PHN patient trials, however, some oral NMDA receptor antagonists have not proved beneficial. 78 Although the use of nonsteroidal anti-inflammatorytype drugs has not been extensively examined in PHN, 79 the active isomer of ibuprofen, (S)-(ϩ)-ibuprofen, can reverse VZV-induced mechanical allodynia. 43 Additionally, the tricyclic antidepressant amitriptyline and the cannabinoid agonist WIN 55,212-2 were found to reverse VZV-induced mechanical allodynia, and both have been found effective in clinical trials for either PHN or other neuropathic conditions. 43, 80, 81 In summary, these preclinical investigations have revealed similarities between a rodent model of chronic pain induced by VZV infection and models of chronic pain from peripheral nerve injury, although more investigation is needed to reveal whether there are physiological changes specific to the VZV model.
Another issue often overlooked in preclinical development of therapeutic approaches is quality of life, which for a neuropathic pain patient is considerably reduced not only as a result of pain levels but in addition by considerable comorbidity, such as anxiety and depression. 82, 83 The animal model of VZV infection has been assessed recently through use of the open-field paradigm to determine anxiety-like behaviors as a measure of integrated pain behavior reflecting pain comorbidities. 43 The VZVinfected animals showed less central locomotion in the open-field, which was positively correlated with degree of mechanical hypersensitivity, with no difference in distance traveled. This finding suggests that VZV infection induced an increase in anxiety-like behavior not due to motor impairment, which (unlike the case with peripheral nerve-injured animals) was not reversed by administration of gabapentin. 43 These findings may help in guiding strategies for the development of novel analgesics for not only sensory but also affective components of VZV-induced persistent pain.
These animal models of VZV-induced persistent pain are models of virus latency, and may not yield information regarding the factors involved in virus reactivation. Reichelt et al. 84 used human DRG xenografts in the SCID-hu mouse to reveal VZV replication. Viral genomic DNA was present, and viral proteins IE62, IE63, and the early ORF47 kinase were expressed in the majority of neurons and satellite cells in VZV-infected DRG xenograft. 84 The first event in VZV reactivation from latency is thought to be polykaryon formation between a single neuron and adjacent satellite cells, allowing VZV virions released from satellite cells to infect nearby satellite cells that surround other neuronal cell bodies. 84 Use of autopsy DRG from HZ patients could identify the role of this satellite cell infection in the clinic, perhaps leading to possible avenues of therapeutic intervention.
CLINICAL EVALUATIONS
Characteristics of the pathophysiological mechanism underlying VZV infection identified in animal models, as described above, demonstrate some parallels with the clinical condition. There are behavioral signs of neuropathic pain and, as in the clinical setting, both sodium channelblocking agents and gabapentin demonstrate some efficacy. Based on results from animal studies, it is hypothesized that distinct pathophysiological mechanisms lead to specific sensory symptoms and signs in patients, which provides a basis for a mechanism-based treatment approach to increasing therapeutic efficacy. 85 Quantitative sensory testing is an important method for creating a detailed sensory profile of the affected area, one that has advantages over standard nerve conduction studies in investigating the function of small fiber afferents. 86 Some groups have identified two major subtypes of distinct sensory symptom constellations in PHN, which may be caused by different pathophysiological mechanisms. 87 
CLINICAL TREATMENTS
Agents generally used for the treatment of neuropathic pain may also show efficacy in PHN because it is a chronic neuropathic pain condition. Currently, selecting appropriate agents in terms of both efficacy and adverse effect profile for any individual is difficult, with treatment often being selected empirically. Improving our understanding of the underlying mechanisms using welldesigned animal models may improve our ability to target treatment effectively.
Postherpetic neuralgia is an area of major therapeutic need; a recent meta-analysis of clinical trial literature revealed that even with the most effective drugs only 30 -50% of patients obtain more than 50% pain relief, often at the cost of serious adverse effects. 79 There is also evidence that early treatment may reduce the duration and severity of PHN. 88 Thus, early diagnosis of both the acute and chronic syndromes may be important in longer-term control. There is evidence that several types of agents may be efficacious in the treatment of PHN. As with all chronic pain syndromes, pharmacological therapy should ideally be part of a multidisciplinary approach to management, but the focus here is on pharmacological strategies.
The use of antiviral therapies in the early stages of the initial HZ episode acts to reduce virus replication and can inhibit the development of prolonged pain. 19, 89 However, antiviral therapy does not prevent pain in all patients, 79, 89, 90 as was also identified in an animal model. [40] [41] [42] [43] The supplementation of antiviral therapy with corticosteroids can be beneficial. 16, 91 Combined antiviral therapy with analgesic agents may also be beneficial. 15, 92 The type of analgesic treatment chosen will depend on the pain severity and coexistent morbidity.
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Antidepressants
Tricyclic antidepressants (TCAs) have a number of possible mechanisms of action, including but not limited to inhibition of norepinephrine and serotonin reuptake and sodium channel blockade. 93 A meta-analysis of TCAs used in the treatment of PHN (amitriptyline, nortriptyline, and desipramine) showed that significant analgesia was obtained, 79 with an earlier analysis also showing TCAs are effective in the treatment of postherpetic pain. 81 The TCAs, however, including amitriptyline (which is the most widely studied TCA for PHN therapy), have a number of adverse effects, including orthostatic hypertension, sedation, memory loss, urinary retention, constipation and cardiac conduction abnormalities. Adverse effects may be a limiting factor in their prescription, especially in the elderly.
The newer combined serotonin-norepinephrine reuptake inhibitors may also be effective in the treatment of PHN. This includes duloxetine, which is one of the few antidepressants licensed for use in neuropathic pain.
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Antiepileptic drugs
Antiepileptic drugs such as gabapentin or pregabalin have been used for the treatment of neuropathic pain. In a randomized controlled trial (RCT) of patients with PHN, those who received gabapentin had significantly greater improvement in pain scores from 1 week, compared with placebo, 95 and another study found a significant reduction (i.e., improvement) in average daily pain score with gabapentin, compared with placebo. 74 The most commonly reported adverse effects are dizziness and somnolence, suggesting that this drug should be titrated slowly in the elderly. The combination of gabapentin and an opioid may result in more effective analgesia at lower doses when compared with either administered alone. 96 Pregabalin, the successor drug to gabapentin, has been shown in three double-blinded RCTs to provide significant pain relief compared with placebo, as well as improvement for pain-related sleep disturbance. 97, 98 One major advantage of pregabalin over gabapentin is its superior bioavailability which makes it easier to use, without the need of long titration periods. If pregabalin is titrated using a flexible dosage schedule, the adverse effect profile is improved while maintaining analgesia.
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Opioid analgesics
Although opioid analgesics are an option for the treatment of neuropathic pain, including PHN, concerns over potential adverse effects, as well as misuse and abuse, have led to recommendations (by the International Association for the Study of Pain special interest group and the European and Canadian consensus panels) for this class of drug to be considered as second-or third-line analgesics. [101] [102] [103] A RCT of oxycodone showed that sustained release of the drug resulted in significant pain relief, compared with placebo, 104 with reduction in both allodynia and spontaneous pain. Double-blind placebocontrolled studies demonstrated that acute infusions of morphine or fentanyl give significant pain relief to PHN patients. 105 A RCT of tramadol indicated that 6 weeks of sustained release resulted in reduced pain and improved quality of life. 106 Overall, the evidence indicates that PHN pain may respond to opioid therapy, with titration of the dose required to achieve optimum efficacy and to minimize adverse effects. Constipation, nausea, and sedation are among the common adverse effects associated with opioid therapy; prophylactic treatment of nausea or constipation is often necessary, and can improve patient compliance.
Topical therapies
Because the patient group most likely to be affected by PHN is often elderly, there are major limitations to using systemic therapies: unacceptable adverse effects can often prevent the dose titration required for efficacy, and may preclude the use of any oral therapies. Topical therapies therefore have clear advantages, in that several established and newer therapies are available, and peripheral mechanisms may be a predominant feature in some PHN patients.
Not all patients fit exactly into one category or the other. Many heterogenous patterns of sensory dysfunction were detected in a large group of PHN patients, 39 and detailed sensory testing in one PHN patient clearly showed areas of relative preservation in close vicinity to impaired thermal sensation, both within the affected dermatome. 107 Furthermore, the sensory patterns showed a variation over the time course of PHN. Nonetheless, continuing investigation of mechanism-based treatment approaches seems to be a promising way to establish an optimal therapy with drugs that address the specific mechanisms in each patient.
A topical local anesthetic may provide analgesia. Lidocaine patches (5%, applied over the area of maximal pain) resulted in significant pain relief in PHN and improved quality of life, 108 -110 and indeed in a RCT there was no significant difference noted between the active (lidocaine) and placebo patch in the incidence of adverse effects. 109 The use of the lidocaine patch has minimal adverse effects, with the most frequent being mild skin irritation at the site of application. 109, 111 Careful characterization of the type of pain, using quantitative sensory testing, indicated that topical lidocaine was more likely to be effective in those patients with signs of predominant degeneration of nociceptive neurons. The striking finding from this study was that patients with nociceptordeprived skin responded significantly to dermal lidocaine therapy. 112 Another topical therapy is capsaicin, an agonist of the transient receptor potential vanilloid 1 receptor (TRPV1), which can lead to excitation and the desensitization of nociceptive afferents. Topical capsaicin (0.075%) has been found to be effective in relieving pain at 6 weeks, compared with placebo, 113 and one 60-minute application of a higher concentration of capsaicin (8%; NGX-4010) resulted in a significantly greater reduction in pain at 2-8 weeks than with a low-concentration (0.04%) control patch. 114 Topical application of capsaicin can often be associated with local irritation and even produces burning pain and hyperalgesia, adverse effects that often lead to discontinuation of its use (even though the reaction typically decreases with repeated applications). The high-dose capsaicin patch is currently in clinical development (e.g., for use with topical anesthetics: NCT00916942, ClinicalTrials.gov). Despite the high concentration, the patch seems to be well tolerated, with minimal adverse effects.
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Interventional therapies
There is limited evidence of good quality for the benefit of any interventional therapies, and further studies are required. Interventional options include sympathetic or other nerve blocks, intrathecal injection, or spinal cord stimulation. Sympathetic nerve blocks have been used for PHN, although these may be more effective in the acute phase. 116 Peripheral nerve blocks have also been used; for example, intercostal nerve blocks were reported to result in long-lasting pain relief for PHN. 117 Pulsed radio-frequency lesioning of the DRG has been assessed in an open case series, and did show some benefit; however, as with most interventions, a study designed to account for the placebo effect is required. 118 Use of lidocaine and methylprednisolone combined (via intrathecal administration) appears to be associated with pain relief in PHN patients, 119 although this has potentially dangerous short-term and long-term adverse effects and the trial has not yet been replicated. 79 Spinal cord stimulation has been used for the treatment of neuropathic pain, and some PHN patients have obtained relief with temporary percutaneous spinal cord stimulation. 120 Given the limited evidence available specifically for interventional therapies in PHN, it is difficult to recommend any particular strategy.
Recent guidelines on evidence-based treatment for neuropathic pain, including PHN, have recommended TCAs, antiepileptics, and topical lidocaine as first-line analgesics, with opioids and tramadol as second-line treatments and topical capsaicin as third-line therapies. [101] [102] [103] Combination therapy may provide additive or synergistic analgesia, although there is little evidence for the benefit or harm provided by such combinations in treatment of PHN.
FUTURE DIRECTIONS
With the introduction of widespread childhood vaccination and also an aging population, the incidence of HZ and thereby PHN is initially expected to increase in the future. The epidemiological impact of varicella and HZ vaccination on HZ and PHN incidence needs to be monitored to allow for more accurate mathematical modeling. One crucial aspect of the ongoing efforts to alleviate PHN is the need for an accepted definition of acute HZ and PHN, to allow for epidemiological surveillance and consistent inclusion criteria for RCTs in PHN patients. Assessment of the effect of PHN and its treatment on quality of life, physical and mental activities, and social relationships of PHN patients is an important factor for future evaluation therapeutic strategies in PHN.
Methods for earlier detection of HZ by patients or clinicians need to be developed, so that adequate preventive treatment can be given before complications such as PHN occur. An important topic for future study is the determination of a biological marker for recovery from PHN. Given that the majority of HZ patients recover from their pain, pruritus, and other symptoms, evaluation of how symptom resolution is brought about could point the way to the development of treatments to hasten or facilitate this process.
